If you have been reading about trans-3-hexenoyl and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Norris was convicted by an 11-1 majority verdict on 3 March 2008 for the murder of four women, and the attempted murder of a fifth (Vera Wilby, aged 90). He was sentenced the following day to life imprisonment, and ordered to serve a minimum term of 30 years in prison. Norris had acted particularly aggressively throughout the trial, banging on the windows of the judge and attacking members of the press when departing the court, shoving two against a wall. Pictures of these attacks were not shown on television for fear of influencing the jury. The judge told Norris when sentencing: "You are, I have absolutely no doubt, a thoroughly evil and dangerous man. You are an arrogant and manipulative man with a real dislike of elderly patients. The most telling evidence was that observation of one of your patients, Bridget Tarpey, who said 'he did not like us old women'. My view is you did not like them because they required too much nursing and were too demanding of your time. You are in my judgment essentially lazy as evidenced by your absences from student placements and work." Norris's mother June Morrison said he had made her so proud as he grew to be successful in his chosen profession. Referred to in the British press as the "Angel of Death", Norris was convicted of killing his victims by injecting them with high levels of insulin. The four victims were:
=== Judges' Costumes === Episode 1: Carla Hall as a bloody victim, Zac Young as Chucky, Stephanie Boswell as the final girl Episode 2: Carla Hall and Stephanie Boswell as terrifying twins (inspired by the Grady Twins from The Shining), Zac Young as an archaeologist (inspired by Indiana Jones) Episode 3: Carla Hall as an evil cheerleader, Zac Young as a vampire glam rock star, Stephanie Boswell as Mistress of the Dark (inspired by Elvira) Episode 4: Carla Hall as an undead fitness instructor, Zac Young as a voodoo doll, Stephanie Boswell as goblin king (inspired by Jareth from the 1986 movie Labyrinth) Episode 5: Carla Hall as dancing queen who only made it to seventeen, Zac Young as tuxedo wolfman, Stephanie Boswell as bloody prom queen (inspired by Carrie White) Episode 6: Carla Hall as deadly disco queen, Zac Young as vicious poodle, Stephanie Boswell as creepy clown Episode 7: Carla Hall as cat lady, Zac Young as devilish boss, Stephanie Boswell as Dollface
=== Inappropriate secretion, associated with hypoglycemia === Hyperinsulinism may also refer to forms of hypoglycemia caused by excessive insulin secretion. In normal children and adults, insulin secretion should be minimal when blood glucose levels fall below 70 mg/dL (3.9 mM). There are many forms of hyperinsulinemic hypoglycemia caused by various types of insulin excess. Some of those that occur in infants and young children are termed congenital hyperinsulinism. In adults, severe hyperinsulinemic hypoglycemia is often due to an insulinoma, an insulin-secreting tumor of the pancreas. Insulin levels above 3 μU/mL are inappropriate when the glucose level is below 50 mg/dL (2.8 mM), and may indicate hyperinsulinism as the cause of the hypoglycemia. The treatment of this form of hyperinsulinism depends on the cause and the severity of the hyperinsulinism, and may include surgical removal of the source of insulin, or a drug such as diazoxide or octreotide that reduces insulin secretion. That spontaneous hyperinsulinism might be a cause of symptomatic hypoglycemia was first proposed by Seale Harris, MD, 1924, in Journal of the American Medical Association. Dr. Seale Harris first diagnosed hyperinsulinism in 1924 and also is credited with the recognition of spontaneous hypoglycemia.
== Structure == Vicilin is made up of one α subunit, a single glycerol, and a phosphate ion. The addition of a copper ligand provides structural integrity. The N-terminus and C-terminus fold into cupin folds to produce conserved β-barrels. Cupin folds cluster in seed storage proteins, and the presence of a metal ligand influences the protein's catalytic action. The C-terminus and N-terminus generate a cupin fold that is symmetrically centered off the axis. This axis is responsible for all copper ligand incorporation. This copper center's structure has four main residues: Cys-338, Tyr-67, His-340, and His-379. The copper ligand is coupled by a trigonal planar structure generated by cysteine's sulfur. The bond formed by a hydroxyl group attached to Tyr-67 is longer than the previous three. The enzymatic activity is connected to copper binding via histidine residues. These copper ligands act catalytically on proteins.
In response, Stalin ordered the Red Army to fight a total war against the Germanic invaders who would exterminate Slavic Russia. Hitler's attack against the Soviet Union (Nazi Germany's erstwhile ally) realigned Stalin's political priorities, from the repression of internal enemies to the existential defence against external attack. The pragmatic Stalin then entered the Soviet Union to the Grand Alliance, a common front against the Axis powers (Nazi Germany, Fascist Italy and the Empire of Japan).
Sources: en.wikipedia.org
Luteinizing hormone subunit beta also known as lutropin subunit beta or LHβ is a polypeptide that in association with an alpha subunit common to all gonadotropin hormones forms the reproductive signaling molecule luteinizing hormone. In humans it is encoded by the LHB gene.
== History == John B. Glen, a veterinarian and researcher at Imperial Chemical Industries (ICI), spent thirteen years developing propofol, an effort for which he was awarded the 2018 Lasker Award for clinical research. Originally developed as ICI 35868, propofol was chosen after extensive evaluation and structure–activity relationship studies of the anesthetic potencies and pharmacokinetic profiles of a series of ortho-alkylated phenols. First identified as a drug candidate in 1973, propofol entered clinical trials in 1977, using a form solubilized in cremophor EL. However, due to anaphylactic reactions to cremophor, this formulation was withdrawn from the market and subsequently reformulated as an emulsion of a soya oil and propofol mixture in water. The emulsified formulation was relaunched in 1986 by ICI (whose pharmaceutical division later became a constituent of AstraZeneca) under the brand name Diprivan. The preparation contains 1% propofol, 10% soybean oil, and 1.2% purified egg phospholipid as an emulsifier, with 2.25% glycerol as a tonicity-adjusting agent, and sodium hydroxide to adjust the pH. Diprivan contains EDTA, a common chelation agent that also acts alone (bacteriostatically against some bacteria) and synergistically with some other antimicrobial agents. Newer generic formulations contain sodium metabisulfite as an antioxidant and benzyl alcohol as an antimicrobial agent. Propofol emulsion is an opaque white fluid due to the scattering of light from the emulsified micelle formulation.
== History == During the mid 20th century, the question "can machines think?" became intriguing and popular among scientists, primarily to add humanistic characteristics to machine behavior. John McCarthy, who was one of the prime researchers of this field, termed this concept of machine intelligence as "artificial intelligence" (AI) during the Dartmouth summer in 1956. AI is usually defined as the capacity of a machine to perform operations that are analogous to human cognitive capabilities. Much research to create AI was done during the 20th century. Also around the mid 20th century, science, especially biology, faced a fast-increasing need to develop a "man-computer symbiosis", to aid scientists in solving problems. For example, the structural analysis of myoglobin, hemoglobin, and other proteins relentlessly needed instrumentation development due to its complexity. In the early 1960s, Joshua Lederberg started working with computers and quickly became tremendously interested in creating interactive computers to help him in his exobiology research. Specifically, he was interested in designing computing systems to help him study alien organic compounds. Lederberg had been heading a team designing instruments for the Mars Viking lander to search for precursor molecules of life in samples of the Mars surface, using a mass spectrometer coupled with a minicomputer.
Additional inner doors reduce the loss of temperature when opening the main door. Icing within the ULT freezer should be reduced to a minimum. Modern ULT freezers employ variable speed drives for both the compressors and fans. This has reduced energy consumption a further 30% to typically 8.5 kWh/day.
=== Freeze drying and UV light === Freeze drying or ultraviolet light exposure are other ways to inhibit mold growth, although they do not kill mold spores permanently. Eliminating mold through these methods is challenging due to paper degradation caused by light exposure over time. There are also some mold species that have preferences for colder temperatures. Freezing and UV exposure are used as a temporary means to stop mold from spreading throughout library collections.
Sources: en.wikipedia.org
The medal for the Nobel Peace Prize was designed by the Norwegian sculptor Gustav Vigeland in 1901. Vigeland's profile sculpture of Alfred Nobel differs from Lindberg's. The dies for Vigeland's peace medal were made by Lindberg as Vigeland was not an engraver. The reverse of the medal features three men in a 'fraternal bond' and the inscription 'Pro pace et fraternitate gentium' ("For the peace and brotherhood of men"). The edge of the medal is inscribed with the year of its awarding, with the name of its recipient and "Prix Nobel de la Paix".
== Buildings == The department spans three buildings. The main departmental building, finished in 1927 (architect Edward Warren) is situated on Tennis Court Road and the nearby Molteno Institute. Both are situated on the Downing Site in central Cambridge. The third location is part of the main hospital building at Addenbrooke's Hospital on the Cambridge Biomedical Campus.
=== Diversity and inclusion campaigns === Cave's ethnic origins have been the subject of debate. She has been featured in Diversity Campaigns by MTV, ABC's Good Morning America, SXSW, 100 Top Women in the World List, The Why Culture, and The Color of STEM.
== Business career == Paetongtarn is the largest shareholder of SC Asset Corporation and a director of the Thaicom Foundation, a benefactor of her family's wealth. As of 2022, she holds a total of 21 companies valued at approximately ฿68 billion (US$2 billion).
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.